全文获取类型
收费全文 | 656篇 |
免费 | 29篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 19篇 |
妇产科学 | 24篇 |
基础医学 | 71篇 |
口腔科学 | 17篇 |
临床医学 | 62篇 |
内科学 | 158篇 |
皮肤病学 | 5篇 |
神经病学 | 23篇 |
特种医学 | 87篇 |
外科学 | 124篇 |
综合类 | 21篇 |
预防医学 | 27篇 |
眼科学 | 7篇 |
药学 | 43篇 |
中国医学 | 2篇 |
肿瘤学 | 23篇 |
出版年
2023年 | 3篇 |
2022年 | 9篇 |
2021年 | 7篇 |
2019年 | 4篇 |
2018年 | 6篇 |
2016年 | 6篇 |
2015年 | 9篇 |
2014年 | 12篇 |
2013年 | 14篇 |
2012年 | 18篇 |
2011年 | 19篇 |
2010年 | 28篇 |
2009年 | 24篇 |
2008年 | 30篇 |
2007年 | 32篇 |
2006年 | 43篇 |
2005年 | 26篇 |
2004年 | 22篇 |
2003年 | 24篇 |
2002年 | 15篇 |
2001年 | 28篇 |
2000年 | 23篇 |
1999年 | 14篇 |
1998年 | 21篇 |
1997年 | 6篇 |
1996年 | 23篇 |
1995年 | 16篇 |
1994年 | 18篇 |
1993年 | 8篇 |
1992年 | 17篇 |
1991年 | 16篇 |
1990年 | 14篇 |
1989年 | 20篇 |
1988年 | 18篇 |
1987年 | 17篇 |
1986年 | 14篇 |
1985年 | 17篇 |
1984年 | 5篇 |
1983年 | 7篇 |
1982年 | 3篇 |
1981年 | 10篇 |
1980年 | 7篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1975年 | 3篇 |
1969年 | 5篇 |
1968年 | 3篇 |
1950年 | 2篇 |
1943年 | 2篇 |
排序方式: 共有716条查询结果,搜索用时 16 毫秒
61.
Treatment goals for the management of lipids and inflammation for patients with coronary artery disease 总被引:2,自引:0,他引:2
Opinion statement Appropriate management of lipids is a central component of risk reduction in patients with coronary artery disease (CAD).
According to the most recent guidelines, low-density lipoprotein cholesterol (LDLC) is the principal target of lipid-lowering
therapy and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are the mainstay of this therapy. The actual
target level of LDL lowering is being reassessed in light of recent clinical trials. Once appropriate LDL lowering has been
achieved, treatment of other targets such as high-density lipoprotein cholesterol (HDLC), triglycerides, and non-HDLC should
be considered. In addition to dyslipidemia, multiple observational studies suggest that inflammatory markers such as C-reactive
protein (CRP) are associated with risk of cardiovascular events and that treatment with statins may lower CRP levels. However,
there are insufficient data at this time supporting treatment of CRP as a principal target in CAD. 相似文献
62.
That sexual symptoms can signal serious underlying disease confirms the importance of sexual enquiry as an integral component of medical assessment. Data on sexual function are sparse in some medical specialties. However, increased scientific understanding of the central and peripheral physiology of sexual response could help to identify the pathophysiology of sexual dysfunction from disease and medical interventions, and also to ameliorate or prevent some dysfunctions. Many common general medical disorders have negative effects on desire, arousal, orgasm, ejaculation, and freedom from pain during sex. Chronic disease also interferes indirectly with sexual function, by altering relationships and self-image and causing fatigue, pain, disfigurement, and dependency. Current approaches to assessment of sexual dysfunction are based on models that combine psychological and biological aspects. 相似文献
63.
64.
65.
Colchicine inhibits pressure-induced tumor cell implantation within surgical wounds and enhances tumor-free survival in mice
下载免费PDF全文
![点击此处可从《The Journal of clinical investigation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Craig DH Owen CR Conway WC Walsh MF Downey C Basson MD 《The Journal of clinical investigation》2008,118(9):3170-3180
Iatrogenic tumor cell implantation within surgical wounds can compromise curative cancer surgery. Adhesion of cancer cells, in particular colon cancer cells, is stimulated by exposure to increased extracellular pressure through a cytoskeleton-dependent signaling mechanism requiring FAK, Src, Akt, and paxillin. Mechanical stimuli during tumor resection may therefore negatively impact patient outcome. We hypothesized that perioperative administration of colchicine, which prevents microtubule polymerization, could disrupt pressure-stimulated tumor cell adhesion to surgical wounds and enhance tumor-free survival. Ex vivo treatment of Co26 and Co51 colon cancer cells with colchicine inhibited pressure-stimulated cell adhesion to murine surgical wounds and blocked pressure-induced FAK and Akt phosphorylation. Surgical wound contamination with pressure-activated Co26 and Co51 cells significantly reduced tumor-free survival compared with contamination with tumor cells under ambient pressure. Mice treated with pressure-activated Co26 and Co51 cells from tumors preoperatively treated with colchicine in vivo displayed reduced surgical site implantation and significantly increased tumor-free survival compared with mice exposed to pressure-activated cells from tumors not pretreated with colchicine. Our data suggest that pressure activation of malignant cells promotes tumor development and impairs tumor-free survival and that perioperative colchicine administration or similar interventions may inhibit this effect. 相似文献
66.
67.
Grigorescu A Ciuleanu T Firoiu E Muresan DR Teodorescu G Basson BR 《Lung cancer (Amsterdam, Netherlands)》2007,57(2):168-174
BACKGROUND: Third-generation platinum-based combinations are established as first-line treatment for advanced non-small cell lung cancer (NSCLC). Non-platinum regimens could be an alternative if they show similar efficacy with better tolerability. This randomized phase II trial compared the objective tumor response rate (ORR) of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin. Secondary objectives included time to disease progression (TTP), overall survival and toxicity. METHODS: Chemo-naive patients with stages III and IV NSCLC and Karnofsky performance status >70 were assigned to receive either (a) gemcitabine 1000mg/m(2) plus vinorelbine 25mg/m(2) on days 1 and 8 for 2 cycles, followed by gemcitabine 1000mg/m(2) on days 1 and 8 plus ifosfamide 2000mg/m(2) on day 1 (GV-GI arm) for 2 cycles or (b) gemcitabine 1250mg/m(2) on days 1 and 8 with cisplatin 70mg/m(2) on day 1 (GC arm) for 4 cycles. RESULTS: Between July 2001 and January 2003, 102 patients were enrolled (50 on the GV-GI arm and 52 on the GC arm). Patient characteristics were balanced between arms (GV-GI arm: median age 59 years, 84% male, 22 stage IIIB, 24 stage IV, 4 stage IIIA; GC arm: median age 56 years, 87% male, 27 stage IIIB, 23 stage IV, 2 stage IIIA). Of the 101 patients evaluable for response, ORR was significantly higher on the GC arm than on the GV-GI arm (25% versus 6%, respectively; p=0.007). No complete responses occurred. TTP was longer on the GC arm than on the GV-GI arm (median 135 and 79 days, respectively), although this difference was not statistically significant (p=0.065). Survival was not significantly different between the arms (median 293 and 197 days, respectively; p=0.16). Although significantly more thrombocytopenia was reported on the GC arm (22% and 4%, respectively; p=0.02), it did not lead to more transfusions (15 transfusions in 5 patients versus 14 transfusions in 6 patients, respectively). There was no significant difference in other safety parameters between treatment arms. CONCLUSIONS: GC appears to produce better response in advanced NSCLC than GV-GI, with a trend towards longer TTP. Except for more thrombocytopenia with GC, similar toxicity profiles were observed. 相似文献
68.
W Oh DK Stevenson JE Tyson BH Morris CE Ahlfors G Jesse Bender RJ Wong R Perritt BR Vohr KP Van Meurs HJ Vreman A Das DL Phelps T Michael O’Shea RD Higgins 《Acta paediatrica (Oslo, Norway : 1992)》2010,99(5):673-678
Objectives: To assess the influence of clinical status on the association between total plasma bilirubin and unbound bilirubin on death or adverse neurodevelopmental outcomes at 18–22 months corrected age in extremely low birth weight infants. Method: Total plasma bilirubin and unbound bilirubin were measured in 1101 extremely low birth weight infants at 5 ± 1 days of age. Clinical criteria were used to classify infants as clinically stable or unstable. Survivors were examined at 18–22 months corrected age by certified examiners. Outcome variables were death or neurodevelopmental impairment, death or cerebral palsy, death or hearing loss, and death prior to follow‐up. For all outcomes, the interaction between bilirubin variables and clinical status was assessed in logistic regression analyses adjusted for multiple risk factors. Results: Regardless of clinical status, an increasing level of unbound bilirubin was associated with higher rates of death or neurodevelopmental impairment, death or cerebral palsy, death or hearing loss and death before follow‐up. Total plasma bilirubin values were directly associated with death or neurodevelopmental impairment, death or cerebral palsy, death or hearing loss, and death before follow‐up in unstable infants, but not in stable infants. An inverse association between total plasma bilirubin and death or cerebral palsy was found in stable infants. Conclusions: In extremely low birth weight infants, clinical status at 5 days of age affects the association between total plasma bilirubin and death or adverse neurodevelopmental outcomes at 18–22 months of corrected age. An increasing level of UB is associated a higher risk of death or adverse neurodevelopmental outcomes regardless of clinical status. Increasing levels of total plasma bilirubin are directly associated with increasing risk of death or adverse neurodevelopmental outcomes in unstable, but not in stable infants. 相似文献
69.
70.